Akebia names Nicholas Grund as Chief Commercial Officer

Akebia Therapeutics announced the appointment of Nicholas Grund as Chief Commercial Officer. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets. Prior to joining Akebia, Grund served as President of Eurofins Transplant Genomics where he steered organizational change and facilitated continuous operating efficiency improvements and revenue growth. He was also Chief Commercial Officer of AMAG Pharmaceuticals where he managed commercial activities across four business units.